These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 3142017

  • 1. Polysaccharide antigens of Pseudomonas aeruginosa.
    Pier GB.
    Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
    [Abstract] [Full Text] [Related]

  • 2. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
    Pier GB.
    Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
    [Abstract] [Full Text] [Related]

  • 3. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
    Pier GB, DesJardin D, Grout M, Garner C, Bennett SE, Pekoe G, Fuller SA, Thornton MO, Harkonen WS, Miller HC.
    Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
    [Abstract] [Full Text] [Related]

  • 4. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB.
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [Abstract] [Full Text] [Related]

  • 5. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa.
    Pier GB, Elcock ME.
    J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359
    [Abstract] [Full Text] [Related]

  • 6. Polysaccharide antigens of Pseudomonas aeruginosa.
    Knirel YA.
    Crit Rev Microbiol; 1990 Aug; 17(4):273-304. PubMed ID: 1698385
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB.
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
    Pier GB.
    J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
    [Abstract] [Full Text] [Related]

  • 16. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
    Meluleni GJ, Grout M, Evans DJ, Pier GB.
    J Immunol; 1995 Aug 15; 155(4):2029-38. PubMed ID: 7636254
    [Abstract] [Full Text] [Related]

  • 17. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF, Zakem-Cloud H, Demko CA, Schreiber JR, Stern RC, Konstan MW, Berger M.
    J Infect Dis; 1995 Aug 15; 172(2):453-61. PubMed ID: 7622889
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.
    Schreiber JR.
    Springer Semin Immunopathol; 1993 Aug 15; 15(2-3):235-46. PubMed ID: 7504840
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.